IFNG and acute myeloid leukemia: Moreover, an additional study suggested that RIPK1/RIPK3 inhibition may be an effective treatment for AML patients when combined with specific chimeric antigen receptor T cells (that express high levels of IFN-γ) or other differentiation inducers in order to repress leukemogenic capacity of AML cells [111].